Moderna Cuts R&D by $1.1B, Focus on Key Approvals
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
- Latest
- Trending
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
Crypto analyst Kaleo predicts strong rallies for Ethereum and Solana, projecting ETH to $4,400 and SOL to $400.
Fovus uses AI to simplify HPC, cutting costs and boosting speed for drug discovery in pharma and biotech sectors.
Discover how to invest in the growing $500B collectibles market with strategic tips and essential insights for beginners.
Kolmogorov-Arnold networks bring transparency to neural networks, offering clearer insights for scientific applications.
Warren Buffett's Berkshire Hathaway reduces stake in Bank of America, impacting stock prices amidst mixed analyst outlooks.
U.S. Bitcoin ETFs saw $1.2B outflows, longest streak yet, but experts say it's a sign of healthy growth.
Tapestry executive testifies potential price hikes, discounts changes in Michael Kors products amid merger talks.
In 2023, crypto scams rose by 45%, with $5.6 billion lost. FBI urges awareness and quicker fraud reporting.
A solo Bitcoin miner beats the odds, securing a $181,000 reward as Bitcoin's price rallies 28% in October.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.